Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Haematologica|September 17, 2016
High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow TransplantationGordon Cook, Simona Iacobelli, Anja van Biezen, et al.
Transplantation|May 15, 2018
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsHeiner Zimmermann, Nina Babel, Daan Dierickx, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 30, 2004
The mutator pathway is a feature of immunodeficiency-related lymphomasAlex Duval, Martine Raphael, Caroline Brennetot, et al.
Blood|October 29, 2005
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 studySylvain Choquet, Veronique Leblond, Raoul Herbrecht, et al.
Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
British Journal of Haematology|November 16, 2012
Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopRoger G Owen, Robert A Kyle, Marvin J Stone, et al.
Leukemia|November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's MacroglobulinemiaIrene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Pageof 7